Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer-Related Lymphedema

L-Dex Found to be a Cost Effective, Reproducible, and Practical Method to Monitor Breast Cancer Patients for Early Signs of Lymphedema

Excerpt from the Press Release:

CARLSBAD, Calif., Oct. 26, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD) is pleased to announce publication of a systematic literature review showing that early detection and intervention of breast cancer-related lymphedema (BCRL) reduces rates of chronic lymphedema in breast cancer patients. The analysis also shows that L-Dex® testing is the detection method with the most extensive evidence of efficacy. L-Dex testing was also found to be cost effective, reproducible, and practical to implement for patient monitoring.

The manuscript, published in Journal of Cancer Survivorship, titled “Reducing rates of chronic breast cancer–related lymphedema with screening and early intervention: an update of recent data” details an analysis of 12 studies including 2,907 breast cancer patients and is available online here: https://link.springer.com/article/10.1007/s11764-022-01242-8.

“The results of this literature review provide further confidence to patients and clinicians that early detection and intervention reduces rates of chronic breast cancer-related lymphedema,” commented Dr. Pat Whitworth, breast surgeon, Director of the Nashville Breast Center, and lead author on the paper. “We have made great strides in improving outcomes for breast cancer patients due, in part, to aggressive screening for early signs of cancer. The same approach can be taken with lymphedema. By using L-Dex for regular monitoring we can find lymphedema early enough to intervene and stop it from becoming a life-long condition.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release